Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases

dc.contributor.authorAlbany, Costantine
dc.contributor.authorEinhorn, Lawrence
dc.contributor.authorGarbo, Lawrence
dc.contributor.authorBoyd, Thomas
dc.contributor.authorJosephson, Neil
dc.contributor.authorFeldman, Darren R.
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2019-09-13T19:32:13Z
dc.date.available2019-09-13T19:32:13Z
dc.date.issued2018-03
dc.description.abstractBACKGROUND: Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates. Expression of CD30 has been observed in testicular cancers, and patients with CD30-expressing embryonal carcinomas have worse progression-free survival and overall survival than those with CD30-negative tumors. The objective of this study (NCT01461538) was to characterize the antitumor activity of brentuximab vedotin in patients with CD30-expressing nonlymphomatous malignancies. Enrolled patients included seven patients with relapsed or refractory germ cell tumors or metastatic sex cord stromal tumors described in this case series. MATERIALS AND METHODS: Forty patients with relapsed or refractory germ cell tumors, metastatic sex cord stromal tumors, or testicular tumors were screened for CD30 expression; 14 patients had tumors that expressed CD30. Seven patients with CD30-expressing testicular cancer were enrolled in the treatment study: five patients with germ cell tumors, one patient with a Leydig cell tumor, and one patient with a Sertoli cell tumor. Patients were treated with brentuximab vedotin at initial doses of 1.8 or 2.4 mg/kg every 3 weeks. Response assessments were performed at cycles 2 and 4 and every 4 cycles thereafter while the patient was receiving treatment. RESULTS: Two of seven patients achieved an objective response, including one durable complete response and one partial response at a single time point. Both responding patients had germ cell tumors. Treatment with brentuximab vedotin was generally well tolerated. CONCLUSION: Treatment of relapsed or refractory germ cell tumors with brentuximab vedotin can induce durable responses with a manageable toxicity profile. IMPLICATIONS FOR PRACTICE: This case series of seven patients with relapsed or refractory CD30-expressing germ cell tumors (GCTs) or sex cord stromal tumors demonstrates that brentuximab vedotin has activity against GCTs and is well tolerated in heavily pretreated patients with these aggressive tumor types. One patient achieved a complete response that has been durable for almost 4 years since the discontinuation of treatment with brentuximab vedotin. Therefore, brentuximab vedotin may be a valuable option for physicians who care for this difficult-to-treat patient population.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationAlbany, C., Einhorn, L., Garbo, L., Boyd, T., Josephson, N., & Feldman, D. R. (2018). Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. The oncologist, 23(3), 316–323. doi:10.1634/theoncologist.2017-0544en_US
dc.identifier.urihttps://hdl.handle.net/1805/20926
dc.language.isoen_USen_US
dc.publisherAlphaMed Pressen_US
dc.relation.isversionof10.1634/theoncologist.2017-0544en_US
dc.relation.journalOncologisten_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectCD30 antigenen_US
dc.subjectClinical trialen_US
dc.subjectGerm cell tumoren_US
dc.subjectImmunoconjugatesen_US
dc.subjectSex cord stromal tumoren_US
dc.titleTreatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Casesen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905693/en_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
onco12342.pdf
Size:
487.72 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: